MarketPulse

clinical-stage biotechnology

4 articles
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Eupraxia Raises $63.2M, Eyes 2028 as Cash-Runway Extends Despite Rising Losses

Eupraxia Pharmaceuticals closed $63.2M offering, boosting cash to $80.5M with runway through H2 2028. Q4 losses doubled to $16.7M amid clinical progress in eosinophilic esophagitis treatment.
EPRXpublic offeringdrug delivery
GlobeNewswire Inc.GlobeNewswire Inc.··Not Specified

Upstream Bio to Present Pipeline Progress at Major Healthcare Conferences

Upstream Bio will present pipeline progress at two March 2026 healthcare conferences, discussing its TSLP receptor antagonist in Phase 2 trials for severe respiratory conditions.
UPBinvestor conferenceverekitug
The Motley FoolThe Motley Fool··Jonathan Ponciano

Perceptive Advisors Doubles Down on Celcuity as Stock Ascends 700% YoY

Perceptive Advisors doubled its Celcuity stake to 5.62% of AUM, making it the fund's second-largest holding. Stock surged 700% YoY ahead of expected FDA approval for lead drug Gedatolisib.
CELCFDA approvalbiotech
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Protara Therapeutics to Present TARA-002 Data at Major Medical Conferences

Protara Therapeutics will present TARA-002 Phase 2 interim data at ASCO GU Symposium, showcasing results for BCG-unresponsive bladder cancer treatment.
TARAinvestor conferencebladder cancer